Preliminary investigations of Pseudomonas aeruginosa vaccine in patients with leukemia and cystic fibrosis.

A heptavalent lipopolysaccharide vaccine against Pseudomonas has been developed. Clinical trials revealed 
a decreased incidence of sepsis and mortality due to Pseudomonas in 
vaccinated patients with burns. If vaccinated, certain groups of immunosuppressed patients 
with cancer may also have a decreased incidence of death associated 
with Pseudomonas. Trials of parenteral vaccination in patients with cystic fibrosis 
show little benefit. Adverse reactions to this vaccine are frequent and 
often limit the dose given. 